Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923075 | 1.00 | PAM (0.70) | PAMMAOBHTTIDO1HDAC3 | |
| Hydroxyamine SCHEMBL30636634 | 0.83 | PAM (0.92) | PAMMAOBIDO1HDAC3TNKS | |
| Hydrazine SCHEMBL29236551 | 0.83 | PAM (0.92) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL156767 | 0.83 | PAM (1.00) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL4296095 | 0.83 | PAM (0.76) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL582727 | 0.83 | PAM (1.00) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL4296099 | 0.83 | PAM (0.76) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL2148302 | 0.83 | PAM (1.00) | PAMMAOBIDO1HDAC3TNKS | |
| SCHEMBL7917269 | 0.82 | PAM (0.53) | PAMMAOBHTTIDO1HDAC3 | |
| SCHEMBL7557624 | 0.82 | PAM (0.47) | PAMMAOBHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981933-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981933-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-105120860-B | Histone deacetylase inhibitors | 生物马林药物股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-111747948-A | Histone deacetylase inhibitors | 生物马林药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3695836-A1 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3524324-A1 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524324-A1 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20190233439-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION | 2019-08-01 | — | — | US | disclosed |
| WO-2012118782-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION (US) | 2012-09-07 | — | — | WO | disclosed |
| US-7084154-B2 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA DRUG DISCLOVERY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-5792444-A | ADMINISTERING LABELED CHEMOTACTIC PEPTIDE WHICH ACCUMULATES AT SITE OF INFECTION OR INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0145265-B1 | ALPHA-AMINO ACIDS THROUGH CATALYTIC REACTION OF CO AND A HYDROXYL COMPOUND WITH ENAMIDES | THE STANDARD OIL COMPANY (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4749786-A | α-amino acids through catalytic reaction of CO and a hydroxyl compound with enamides | THE STANDARD OIL COMPANY (US) | 1988-06-07 | — | — | US | disclosed |
| US-4710574-A | HYDROCARBOXYLATION OF UNSATURATED AMIDES | THE STANDARD OIL COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0145265-A2 | Alpha-amino acids through catalytic reaction of CO and a hydroxyl compound with enamides | THE STANDARD OIL COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233439-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PAM 4821/4885MAOB 2779/4885HTT 438/4885 |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PAM 4821/4885MAOB 2779/4885HTT 438/4885 |
| US-10981933-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | PAM 4821/4885MAOB 2779/4885HTT 438/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | PAM 659/4885MAOB 420/4885HTT 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.